SRT 015
Alternative Names: SRT-015Latest Information Update: 28 Dec 2024
Price :
$50 *
At a glance
- Originator Seal Rock Therapeutics
- Developer Genfit; Seal Rock Therapeutics
- Class Anti-inflammatories; Antidementias; Antifibrotics; Eye disorder therapies; Hepatoprotectants; Skin disorder therapies; Small molecules
- Mechanism of Action MAP kinase kinase kinase 5 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Liver disorders
- No development reported Alcoholic hepatitis; Liver failure; Non-alcoholic steatohepatitis
- Discontinued Amyotrophic lateral sclerosis; Retinal disorders; Skin disorders
Most Recent Events
- 28 Dec 2024 No recent reports of development identified for preclinical development in Liver-failure in USA (IV)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Alcoholic-hepatitis(In volunteers) in Australia (PO)
- 28 Jun 2024 No recent reports of development identified for phase-I development in Non-alcoholic-steatohepatitis(In volunteers) in Australia (PO)